Neural repair strategies for Parkinson's disease: Insights from primate models

Cell Transplantation

Volumn 15, Issue 3, 2006, Pages 251-265

  Soderstrom, Katherine ^a   O'Malley, Jennifer ^b   Steece Collier, Kathy ^b   Kordower, Jeffrey H ^a,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Research Center for Brain Repair   (United States)

Author keywords

Animal models; Nonhuman primates; Parkinson's disease; Therapeutics

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MANEB; OXIDOPAMINE; PARAQUAT; ROTENONE;

BRAIN DEPTH STIMULATION; BRAIN GRAFT; DISEASE MODEL; DOPAMINE BRAIN LEVEL; EMBRYONIC STEM CELL; GENE DELIVERY SYSTEM; GLOBUS PALLIDUS; MOTOR CORTEX; NERVE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TREATMENT INDICATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CELL TRANSPLANTATION; DEEP BRAIN STIMULATION; DISEASE MODELS, ANIMAL; FUNGICIDES, INDUSTRIAL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HERBICIDES; HUMANS; MANEB; NERVE DEGENERATION; OXIDOPAMINE; PARAQUAT; PARKINSON DISEASE; PESTICIDES; PRIMATES; ROTENONE;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 33646576182     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783982025     Document Type: Review

References (124)

1. Ahlskog, J. E.; Muenter, M. D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3):448-458; 2001.
2. Albanese, A.; Granata, R.; Gregori, B.; Piccardi, M.; Colosimo, C.; Tonali, P. Chronic administration of 1-methyl-4-phenyl-1,1,2,3,6- tetrahydropyrindine to monkeys: behavioral, morphological and biochemical correlates. Neuroscience 55:823-832; 1993.
3. Aminoff, M. J. Pharmacologic management of parkinsonism and other movement disorders. In: Katzung, B. G., ed. Basic and clinical pharmacology, 9th ed. New York: McGraw Hill; 2004.
4. Annett, L. E.; Martel, F. L.; Rogers, D. C.; Ridley, R. M.; Baker, H. F.; Dunnett, S. B. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 125(2):228-246; 1994.
5. Annett, L. E.; Torres, E. M.; Ridley, R. M.; Baker, H. F.; Dunnett, S. B. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions. Exp. Brain Res. 103(3):355-371; 1995.
6. Annett, L. E.; Torres, E. M.; Clarke, D. J.; Ishida, Y.; Barker, R. A.; Ridley, R. M.; Baker, H. F.; Dunnett, S. B. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. Cell Transplant. 6(6):557-569; 1997.
7. Backlund, E. O.; Granberg, P. O.; Hamberger, B.; Knutsson, E.; Martensson, A.; Sedvall, G.; Seiger, A.; Olson, L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62(2):169-173; 1985.
8. Bakay, R. A.; Barrow, D. L.; Fiandaca, M. S.; Iuvone, P. M.; Schiff, A.; Collins, D. C. Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation. Ann. NY Acad. Sci. 495:623-640; 1987.
9. Bankiewicz, K. S.; Plunkett, R. J.; Kophin, I. J.; Jacobwitz, D. M.; London, W. T.; Oldfield, E. H. Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. Prog. Brain Res. 78:543-549; 1988.
10. Bankiewicz, K.; Palmatier, M.; Plunkett, R. J.; Cummins, A.; Oldfield, E. H. Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. J. Neurosurg. 81:869-876; 1994.
11. Barlow, B.; Richfield, E.; Cory-Slechta, D.; Thiruchelvam, M. A fetal risk factor for Parkinson's disease. Dev. Neurosci. 26(1):11-23; 2004.
12. Barlow, B. K.; Lee, D. W.; Cory-Slechta, D. A.; Opanashuk, L. A. Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. Neurotoxicology 26(1):63-75; 2005.
13. Behrstock, S.; Ebert, A.; McHugh, J.; Vosberg, S.; Moore, J.; Schneider, B.; Capowski, E.; Hei, D.; Kordower, J.; Aebischer, P.; Svendsen, C. N. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther. 13:379-388; 2006.
14. Bezard, E.; Dovero, S.; Prunier, C.; Ravenscroft, P.; Chalon, S.; Guilloteau, D.; Crossman, A. R.; Bioulac, B.; Brotchie, J. M.; Gross, C. E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned macaque model of Parkinson's disease. J. Neurosci. 21(17):6853-6861; 2001.
15. Björklund, A.; Stenevi, U.; Svendgaard, N. Growth of transplanted monoaminergic neurons into the adult hippocampus along the perforant path. Nature 262(5571):787-790; 1976.
16. Borlongan, C. V.; Sanberg, P. R. Neural transplantation for treatment of Parkinson's disease. Drug Discov. Today 7(12):674-682; 2002.
17. Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2):197-211; 2003.
18. Brownell, A. L.; Canales, K.; Chen, Y. I.; Jenkins, B. G.; Owen, C.; Livni, E.; Yu, M.; Cicchett, F.; Sanchez-Pernaute, R.; Isacson, O. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage 20:1064-1075; 2003.
19. Brundin, P.; Pogarell, O.; Hagell, P.; Piccini, P.; Widner, H.; Schrag, A.; Kupsch, A.; Crabb, L.; Odin, P.; Gustavii, B.; Björklund, A.; Brooks, D. J.; Marsden, C. D.; Oertel, W. H.; Quinn, N. P.; Rehncrona, S.; Lindvall, O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123(Part 7):1880-1890; 2000.
20. Burns, R. S.; Chiueh, C. C.; Markey, S. P.; Ebert, M. H.; Jacobowitz, D. M.; Kopin, I. J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydorpyridine. Proc. Natl. Acad. Sci. USA 80:4546-4550; 1983.
21. Cass, W.; Gerhardt, G. A.; Zhang, Z.; Ovadia, A.; Gash, D. M. Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions. Neurosci. Lett. 185:52-55; 1995.
22. Centonze, D.; Gubellini, P.; Rossi, S.; Picconi, B.; Pisani, A.; Bernardi, G.; Calabresi, P.; Baunez, C. Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience 133:831-840; 2005.
23. Del Fiacco, M.; Quarto, M.; Serra, M. P.; Follesa, P.; Lai, M. L.; Bachis, A. Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem: An immunohistochemical study of prenatal, neonatal and adult brains. J. Chem. Neuroanat. 23(1):29-48; 2002.
24. Diaz-Corrales, F.; Asanuma, M.; Miyazaki, I.; Miyoshi, K.; Ogawa, N. Rotenone induces aggregation of gamma-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration. Neuroscience 133(1):117-135; 2005.
25. DiMonte, D. A.; McCormack, A.; Petzinger, G.; Janson, A. M.; Quik, M.; Langsten, W. J. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15(3):459-466; 2000.
26. Drouot, X.; Oshino, S.; Jarraya, B.; Besret, L.; Kishima, H.; Remy, P.; Dauguet, J.; Lefaucheur, J. P.; Dolle, F.; Conde, F.; Bottlaender, M.; Peschanski, M.; Keravel, Y.; Hantraye, P.; Palfi, S. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron 44(5):769-778; 2004.
27. During, M. J.; Kaplitt, M. G.; Stern, M. B.; Eidelberg, D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 12(12):1589-1591; 2001.
28. Elsworth, J. D.; Taylor, J. R.; Sladek, J. R.; Collier, T. J.; Redmond, D. E.; Roth, R. H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95(2):399-408; 2000.
29. Englund, U.; Björklund, A.; Wictorin, K. Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Brain Res. Dev Brain Res. 134(1-2):123-141; 2002.
30. Eslamboli, A.; Baker, H.; Ridley, R.; Annett, L. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Exp. Neurol. 183:418-429; 2003.
31. Eslamboli, A.; Cummings, R. M.; Ridley, R. M.; Baker, H. F.; Muzyczka, N.; Burger, C.; Mandel, R. J.; Kirik, D.; Annett, L. E. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184(1):536-548; 2003.
32. Eslamboli, A. Marmoset monkey models of Parkinson's disease. Which model, when and why? Brain Res. Bull. 68:140-149; 2005.
33. Fiandaca, M. S.; Kordower, J. H.; Hansen, J. T.; Gash, D. M. Adrenal medullary tissue grafting in Parkinson's disease. J. Neurosurg. 69(1):150-152; 1988.
34. Firestone, J. A.; Smith-Weller, T.; Franklin, G.; Swanson, P.; Longstreth, Jr., W. T.; Checkoway, H. Pesticides and risk of Parkinson disease: A population-based case-control study. Arch. Neurol. 62(1):91-95; 2005.
35. Fleming, S. M.; Zhu, C.; Femagut, P. O.; Mehta, A.; Dicarlo, C. D.; Seaman, R. L.; Chesselet, M. F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 187(2):418-429; 2004.
36. Freed, C. R.; Greene, P. E.; Breeze, R. E.; Tsai, W. Y.; DuMouchel, W.; Kao, R.; Dillon, S.; Winfield, H.; Culver, S.; Trojanowski, J. Q.; Eidelberg, D.; Fahn, S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344(10):710-719; 2001.
37. Gill, S. S.; Patel, N. K.; Hotton, G. R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D. J.; Svendsen, C. N.; Heywood, P. Direct brain infusion of glial cell line-dervied neurotrophic factor in Parkinson disease. Nat. Med. 9(5):589-595; 2003.
38. Goetz, C. G.; Olanow, C. W.; Koller, W. C.; Penn, R. D.; Cahill, D.; Morantz, R.; Stebbins, G.; Tanner, C. M.; Klawans, H. L.; Shannon, K. M. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N. Engl. J. Med. 320(6):337-341; 1989.
39. Greenamyre, J.; MacKenzie, G.; Peng, T.; Stephans, S. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66:85-97; 1999.
40. Grondin, R.; Zhang, Z.; Yi, A.; Cass, W. A.; Maswood, N.; Andersen, A. H.; Elsberry, D. D.; Klein, M. C.; Gerhardt, G. A.; Gash, D. M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125(Pt. 10):2191-2201; 2002.
41. Hagell, P.; Schrag, A.; Piccini, P.; Jahanshahi, M.; Brown, R.; Rhencrona, S.; Widner, H.; Brundin, P.; Rothwell, J. C.; Odin, P.; Wenning, G. K.; Morrish, P.; Gustavii, B.; Björklund, A.; Brooks, D. J.; Marsden, C. D.; Quinn, N. P.; Lindvall, O. Sequential bilateral transplanation in Parkinson's disease: Effects of the second graft. Brain 122(Pt. 6):1121-1132; 1999.
42. Hashimoto, T.; Hder, C. M.; Okun, M. S.; Patrick, S. K.; Vitek, J. L. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J. Neurosci. 23(5):1916-1923; 2003.
43. Hauser, R. A.; Freeman, T. B.; Snow, B. J.; Nauert, M.; Gauger, L.; Kordower, J. H.; Olanow, C. W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch. Neurol. 56(2):179-187; 1999.
44. Hirsch, E. C.; Duyckaerts, C.; Javoy-Agid, F.; Hauw, J. J.; Agid, Y. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? Ann. Neurol. 27(6):676-682; 1990.
45. Hitchcock, E. Stereotactic neural transplantation. Stereotact. Funct. Neurosurg. 62(1-4):120-133; 1994.
46. Hoffer, B.; Seiger, A.; Ljungberg, T.; Olson, L. Electrophysiological and cytological studies of brain homografts in the anterior chamber of the eye: Maturation of cerbellar cortex in oculo. Brain Res. 79(2):165-184; 1974.
47. Hoffer, B.; Seiger, A.; Freedman, R.; Olson, L.; Taylor, D. Electrophysiology and cytology of hippocampal formation transplants in the anterior chamber of the eye. II. Cholinergic mechanisms. Brain Res. 119(1):107-132; 1977.
48. Jan, C.; Pessiglione, M.; Tremblay, L.; Tande, D.; Hirsch, E. C.; Francois, C. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys. Eur. J. Neurosci. 18:2082-2086; 2003.
49. Jankovic, J. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations. Mov. Disord. 20(Suppl. 11):S11-16; 2005.
50. Jenner, P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat. Disord. 9:131-137; 2003.
51. Jiao, S. S.; Zhang, W. C.; Cao, J. K.; Zhang, Z. M.; Wang, H.; Ding, M. C.; Zhang, Z.; Sun, J. B.; Sun, Y. C.; Shi, M. T. Study of adrenal medullary tissue transplantation to striatum in parkinsonism. Prog. Brain Res. 78:575-580; 1988.
52. Kirik, D.; Rosenblad, C.; Björklund, A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:259-277; 1998.
53. Kirik, D.; Rosenblad, C.; Burger, C.; Lundberg, C.; Johansen, T.; Muzycka, N.; Mandel, R.; Björklund, A. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22(7):2780-2791; 2002.
54. Kirik, D.; Annett, L.; Burger, C.; Muzyczka, N.; Mandel, R.; Björklund, A. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100(5):2884-2889; 2003.
55. Kordower, J. H.; Cochran, E.; Penn, R. D.; Goetz, C. G. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann. Neurol. 29(4):405-412; 1991.
56. Kordower, J. H.; Palfi, S.; Chen, E. Y.; Ma, S. Y.; Sendera, T.; Cochran, E. J.; Cochran, E. J.; Mufson, E. J.; Penn, R.; Goetz, C. G.; Comella, C. D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46(3):419-424; 1999.
57. Kordower, J. H.; Emborg, M. E.; Bloch, J.; Ma, S. Y.; Chu, Y.; Leventhal, L.; McBride, J.; Chen, E. Y.; Palfi, S.; Roitberg, B. Z.; Brown, W. D.; Holden, J. E.; Pyzalski, R.; Taylor, M. D.; Carvey, P.; Ling, Z.; Trono, D.; Hantraye, P.; Deglon, N.; Aebischer, P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290(5492):767-773; 2000.
58. Kowall, N.; Hantraye, P.; Brouillet, E.; Beal, M. F.; McKee, A.; Ferrante, R. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11(1):211-213; 2000.
59. Kowamoto, Y.; Nakamura, S.; Matsuo, A.; Akiguchi, I.; Shibasaki, H. Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system. Neuroscience 100(4):701-712; 2000.
60. Krack, P.; Benazzouz, A.; Pollak, P.; Limousin, P.; Piallat, B.; Hoffmann, D.; Xie, J.; Benabid, A. L. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov. Disord. 13(6):907-914; 1998.
61. Krack, P. Parkinson's disease: Deep brain stimulation. Rev. Neurol. (Paris) 158(122):135-141; 2002.
62. Kupsch, A.; Sautter, J.; Gotz, M. E.; Breithaupt, W.; Schwarz, J.; Youdim, M. B. H.; Riederer, P.; Gerlach, M.; Oertel, W. H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with segegiline. J. Neural Transm. 108:985-1009; 2001.
63. Langston, J.; Ballard, P.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980; 1983.
64. Lieberman, A. N. The use of adrenal medullary and fetal grafts as a treatment for Parkinson disease. NY State J. Med. 88(6):287-289; 1988.
65. Limousin, P.; Pollak, P.; Benazzouz, A.; Hoffmann, D.; Broussolle, E.; Perret, J. E.; Benabid, A. L. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov. Disord. 10(5):672-674; 1995.
66. Limousin, P.; Krack, P.; Pollak, P.; Benazzouz, A.; Ardouin, C.; Hoffmann, D.; Benabid, A. L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339(16):1105-1111; 1998.
67. Lindvall, O.; Backlund, E. O.; Farde, L.; Sedvall, G.; Freedman, R.; Hoffer, B.; Nobin, A.; Seiger, A.; Olson, L. Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen. Ann. Neurol. 22(4):457-468; 1987.
68. Lo Bianco, C.; Ridet, J.; Schenider, B.; Deglon, N.; Aebischer, P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99(16):10813-10818; 2002.
69. Lo Bianco, C.; Deglon, N.; Pralong, W.; Aebischer, P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 17(2):283-289; 2004.
70. Ma, Y.; Feigin, A.; Dhawan, V.; Fukuda, M.; Shi, Q.; Greene, P.; Breeze, R.; Fahn, S.; Freed, C.; Eidelberg, D. Dyskinesia after fetal cell transplantation for Parkinsonism: A PET study. Ann. Neurol. 52(5):628-634; 2003.
71. Manning-Bog, A.; McCormack, A.; Li, J.; Uversky, V.; Fink, A.; Di Monte, D. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice. J. Biochem. 277(3):1641-1644; 2002.
72. Maurice, N.; Thierry, A. M.; Glowinski, J.; Deniau, J. M. Spontaneous and evoked activity of substantia nigra pars reticulata neurons during high-frequency stimulation of subthalamic nucleus. J. Neurosci. 23(30): L9929-9936; 2003.
73. Meissner, W.; Leblois, A.; Hansel, D.; Bioulac, B.; Gross, C. E.; Benazzouz, A.; Boraud, T. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain 128(Pt. 10):2372-2382; 2005.
74. Mitsumoto, Y.; Watanabe, A.; Mori, A.; Koga, N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248(3):660-663; 1998.
75. Morihisa, J. M.; Nakamura, R. K.; Freed, W. J.; Mishkin, M.; Wyatt, R. J. Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp. Neurol. 84(3):643-653; 1984.
76. Nikkhah, G.; Cunningham, M. G.; Jodicke, A.; Knappe, U.; Björklund, A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res. 633(1-2):133-143; 1994.
77. Nikkhah, G.; Olsson, M.; Eberhard, J. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: A detailed account of the methodology. Neuroscience 63:57-72; 1994.
78. Nussbaum, R.; Polymeropoulous, M. Genetics of Parkinson's disease. Hum. Mol. Genet. 6(10):1687-1691; 1997.
79. Nutt, J. G.; Burcheil, K. J.; Comella, C. L.; Jankovic, J.; Lang, A. E.; Laws, E. R.; Lozano, A. M.; Penn, R. D.; Simpson, R. K.; Stacy, M.; Wotten, G. F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1):69-73; 2003.
80. Ohmachi, S.; Watanabe, Y.; Mikami, T.; Kusu, N.; Ibi, T.; Akaike, A.; Itoh, N. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem. Biophys. Res. Commun. 277(2):355-360; 2000.
81. Oiwa, Y.; Eberling, J. L.; Nigy, D.; Pivirotto, P.; Emborg, M. E.; Bankiewicz, K. Overlesioned hemiparkinsonian nonhuman primate model: Correlation between clinical, neurochemical and histochemical changes. Front. Biosci. 8:a155-166; 2003.
82. Olanow, C. W.; Tatton, W. G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:123-144; 1999.
83. Olanow, C. W.; Goetz, C. G.; Kordower, J. H.; Stoessl, A. J.; Sossi, V.; Brin, M. F.; Shannon, K. M.; Nauert, G. M.; Perl, D. P.; Godbold, J.; Freeman, T. B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54(3):403-414; 2003.
84. Olson, L.; Seiger, A. Early prenatal ontogeny of central monoamine neurons in the rat: Fluorescence histochemical observations. Z. Anat. Entwicklungsgesetz 137(3):301-316; 1972.
85. Olson, L.; Seiger, A. Locus coeruleus: fiber growth regulation in oculo. Med. Biol. 54(2):142-145; 1976.
86. Panov, A.; Dikalov, S.; Shalbuyeva, N.; Taylor, G.; Sherer, T.; Greenamyre, J. Rotenone model of Parkinson disease: Multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 280(51):42026-42035; 2005.
87. Parkin, S.; Nandi, D.; Giladi, N.; Joint, C.; Gregory, R.; Bain, P.; Scott, R.; Aziz, T. Z. Lesioning the subthalamic nucleus in the treatment of Parkinson's disease. Stereotact. Funct. Neurosurg. 77(1-4):68-72; 2001.
88. Parkinson's Disease Foundation, www.pdf.org; 2005.
89. Patel, N. K.; Bunnage, M.; Plaha, P.; Svendsen, C. N.; Heywood, P.; Gill, S. S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann. Neurol. 57(2):298-302; 2005.
90. Penn, R. D.; Goetz, C. G.; Tanner, C. M.; Klawans, H. L.; Shannon, K. M.; Comella, C. L. The adrenal medullary transplant operation for Parkinson's disease: Clinical observations in five patients. Neurosurgery 22(6 Pt. 1):999-1004; 1988.
91. Petzinger, G.; Langston, J. The MPTP-lesioned non-human primate: A model for Parkinson's disease. In: Marwah, J.; Teiltelbaum, H., eds. Advances in neurodegenerative disorders: Parkinson's disease. Scottsdale: Prominent Press; 1998.
92. Pifl, C.; Schingnitz, G.; Hornykiewicz, O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idieopathic Parkinson's disease. Neurosci. Lett. 92(2):228-233; 1988.
93. Plunkett, R. J.; Bankiewicz, K. S.; Cummins, A. C.; Miletich, R. S.; Schwartz, J. P.; Oldfield, E. H. Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. J. Neurosurg. 73(6):918-926; 1990.
94. Pollack, A. E.; Harrison, M. B.; Wooten, G. F.; Fink, J. S. Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res. 631(1):161-166; 1993.
95. Przedborski, S.; Levivier, M.; Jiang, H.; Ferreira, M.; Jackson-Lewis, V.; Donaldson, D.; Togasaki, D. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647; 1995.
96. Przedborski, S.; Jackson-Lewis, V.; Naini, A. B.; Jakowec, M.; Petzinger, G.; Miller, R.; Akram, M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): A technical review of its utility and safety. J. Neurochem. 76(5):1265-1274; 2001.
97. Purisai, M. G.; McCormack, A. L.; Langsten, W. J.; Johnston, L. C.; DiMonte, D. A. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 20(3):898-906; 2005.
98. Reading, P.; Dunnett, S. 6-Hydroxydopamine lesions of nigrostriatal neurons as an animal model of Parkinson's disease. In: Woodruf, M.; Nonneman, A., eds. Toxin-induced models of neuroglogical disorders. New York: Plenum Press; 1994.
99. Redmond, Jr., D. E.; Naftolin, F.; Collier, T. J.; Leranth, C.; Robbins, R. J.; Sladek, C. D.; Roth, R. H.; Sladek, Jr., J. R. Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. Science 242(4879):768-771; 1988.
100. Richardson, J.; Quan, Y.; Sherer, T.; Greenamyre, J.; Miller, G. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 88(1):193-201; 2005.
101. Rodriguez, M. C.; Guridi, O. J.; Alvarez, L.; Mewes, K.; Macias, R.; Vitek, J.; DeLong, M. R.; Obeso, J. A. The subthalamic nucleus and tremor in Parkinson's disease. Mov. Disord. 13(Suppl. 3):111-118; 1998.
102. Sachs, C.; Jonsson, G. Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol. 24:1-8; 1975.
103. Saravanan, K. S.; Sindhu, K. M.; Mohanakumar, K. P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res. 1049(2):147-155; 2005.
104. Schueler, S. B.; Ortega, J. D.; Sagen, J.; Kordower, J. H. Robust survival of isolated bovine adrenal chromaffinn cells following intrastriatal transplantation: A novel hypothesis of adrenal graft viability. J. Neurosci. 13(10):4496-4510; 1993.
105. Schultz, W. MPTP-induced parkinsonism in monkeys: Mechanism of action, selectivity and pathophysiology. Gen. Pharmacol. 19:153-161; 1988.
106. Schwarting, R.; Huston, J. The unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 49(3):215-266; 1996.
107. Sladek, Jr., J. R.; Redmond, Jr., D. E.; Collier, T. J.; Haber, S. N.; Elsworth, J. D.; Deutch, A. Y.; Roth, R. H. Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. Prog. Brain Res. 71:309-323; 1987.
108. Sladek, Jr., J. R.; Redmond, Jr., D. E.; Roth, R. H. Transplantation of fetal neurons in primates. Clin. Res. 36(3):200-204; 1988.
109. Sladek, Jr., J. R.; Elsworth, J. D.; Roth, R. H.; Evans, L. E.; Collier, T. J.; Cooper, S. J.; Taylor, J. R.; Redmond, Jr., D. E. Fetal dopamine cell survival after transplantation is dramatically improved at a critical donor gestational age in nonhuman primates. Exp. Neurol. 122(1):16-27; 1993.
110. Sladek, Jr., J. R.; Collier, T. J.; Elsworth, J. D.; Roth, R. H.; Taylor, J. R.; Redmond, Jr., D. E. Intrastriatal grafts from multiple donors do not result in a proportional increase in survival of dopamine neurons in non-human primates. Cell Transplant. 7(2):87-96; 1998.
111. Stenevi, U.; Björklund, A.; Svendgaard, N. A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival. Brain Res. 114(1):1-20; 1976.
112. Svendsen, C. N.; Caldwell, M. A.; Shen, J.; ter Borg, M. G.; Rosser, A. E.; Tyers, P.; Karmiol, S.; Dunnett, S. B. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp. Neurol. 148(1):135-146; 1997.
113. Svendsen, C. N.; ter Borg, M. G.; Armstrong, R. J.; Rosser, A. E.; Chandran, S.; Ostenfeld, T.; Caldwell, M. A. A new method for the rapid and longterm growth of human neural precursor cells. J. Neurosci. Methods 85(2):141-152; 1998.
114. Takagi, Y.; Takahashi, J.; Saiki, H.; Morizane, A.; Hayashi, T.; Kishi, Y.; Fukuda, H.; Okamoto, Y.; Koyanagi, M.; Ideguchi, M.; Hayashi, H.; Imazato, T.; Kawasaki, H.; Suemori, H.; Omachi, S.; Iida, H.; Itoh, N.; Nakatsuji, N.; Sasai, Y.; Hashimoto, N. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J. Clin. Invest. 115(1):102-109; 2005.
115. Taylor, J. R.; Schmieder, G. J.; Shimizu, T.; Tie, C.; Streilein, J. W. Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. Cell Transplant. 4(1):13-26; 1995.
116. Taylor, J.; Elsworth, J.; Roth, R.; Sladek, Jr., J.; Redmond, Jr., D. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 81(3):745-755; 1997.
117. Tetrud, J.; Längsten, J.; Redmond, D.; Roth, R.; Sladek, Jr., J.; Angel, R. MPTP-induced tremor in human and non-human primates. Neurology 36:308; 1986.
118. Thiruchelvam, M.; Brockel, B. J.; Richfield, E. K.; Baggs, R. B.; Cory-Slechta, D. A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease. Brain Res. 873(2):225-234; 2000.
119. Ungerstedt, U. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5:107-110; 1968.
120. Uversky, V. Neurotoxicant-induced animal models of Parkinson's disease; Understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 318(1):225-241; 2004.
121. Wichmann, T.; Bergman, H.; DeLong, M. R. The primate subthalamic nucleus. I. Functional properties in intact animals. J. Neurophysiol. 72(2):494-506; 1994.
122. Yang, W.; Tiffany-Castiglioni, E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: Relevance to the dopaminergic pathogenesis. J. Toxicol. Environ. Health A 68(22):1939-1961; 2005.
123. Zhang, J.; Fitsanakis, V.; Gu, G.; Jing, D.; Ao, M.; Amarnath, V.; Montine, T. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: A link through mitochondrial dysfunction. J. Neurochem. 84(2):336-346; 2003.
124. Zhu, C.; Vorc'h, P.; Fernagut, P. O.; Fleming, S. M.; Lacan, S.; Dicarlo, C. D.; Seaman, R. L.; Chesselet, M. F. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 478(4):418-426; 2004.